Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Research Article

A Prospective Study on the Incidence and Severity of Paclitaxel-induced Peripheral Neuropathy in the Indian Population

Author(s): A.M. George, M.A. Arya, S.K. Joseph, A. Philip, R. Reghu* and K.M. Sam

Volume 18, Issue 4, 2022

Published on: 10 October, 2022

Page: [278 - 284] Pages: 7

DOI: 10.2174/1573394718666220610185525

Price: $65

Abstract

Background: Despite the high efficacy rate of paclitaxel, physicians are compelled to discontinue the regimen due to its prevailing neurotoxicity and myelosuppressive effects, thus not achieving the desired clinical outcomes. The neurotoxicity studies of paclitaxel have been mostly performed on upper dose limits (>275mg/m2), and little information is available on lower doses. Since there is a lack of such studies on the Indian population, the medical professionals are unable to analyze at what cumulative dose does paclitaxel show maximum severity of peripheral neuropathy.

Methods: This is a prospective observational study conducted for 1 year in patients undergoing paclitaxel therapy. These patients were evaluated for the incidence and severity of paclitaxel-induced peripheral neuropathy during the first 6 cycles using the QLQ-CIPN questionnaire. We also identified the cumulative dose at which most patients developed peripheral neuropathy and each patient’s quality of life using EORTC QLQ C30.

Results: Out of 85 patients, 76 developed peripheral neuropathy during the first 6 cycles. It was observed that the severity of peripheral neuropathy increased in each cycle of therapy. The overall quality of life of patients decreased with therapy, and at a cumulative dose of 525mg/m2, most of the patients (40%) developed symptoms of peripheral neuropathy.

Conclusion: The incidence and severity of peripheral neuropathy increased with each cycle, leading to a significant reduction in the quality of life of patients post 6 cycles. Moreover, a high cumulative dose may limit the paclitaxel therapy.

Keywords: Quality of life (QOL), paclitaxel, peripheral neuropathy, myelosuppression, cumulative dose, texane.

[1]
Velasco R, Bruna J. Taxane-induced peripheral neurotoxicity. Toxics 2015; 3(2): 152-69.
[http://dx.doi.org/10.3390/toxics3020152] [PMID: 29056655]
[2]
Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24(10): 1633-42.
[http://dx.doi.org/10.1200/JCO.2005.04.0543] [PMID: 16575015]
[3]
Prevention and treatment of chemotherapy-induced peripheral neuropathy. Available from: https://www.uptodate.com/.../prevention-and-treatment-of-chemotherapy- (Accessed on: April 18, 2017).
[4]
Hilpert F, Stähle A, Tomé O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy-a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005; 13(10): 797-805.
[http://dx.doi.org/10.1007/s00520-005-0782-y] [PMID: 16025262]
[5]
Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropa-thy with quantitative sensory testing. J Neurooncol 1997; 35(1): 47-53.
[http://dx.doi.org/10.1023/A:1005805907311] [PMID: 9266440]
[6]
Cleeland CS, Farrar JT, Hausheer FH. Assessment of cancer-related neuropathy and neuropathic pain. Oncologist 2010; 15 (Suppl. 2): 13-8.
[http://dx.doi.org/10.1634/theoncologist.2009-S501] [PMID: 20489192]
[7]
Kuroi K, Shimozuma K, Ohashi Y, et al. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer 2009; 17(8): 1071-80.
[http://dx.doi.org/10.1007/s00520-008-0550-x] [PMID: 19089463]
[8]
Gould N, Sill MW, Mannel RS, et al. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125(1): 54-8.
[http://dx.doi.org/10.1016/j.ygyno.2011.12.417] [PMID: 22155262]
[9]
Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: A gynecologic oncology group study. Int J Gynecol Cancer 2007; 17(2): 387-93.
[http://dx.doi.org/10.1111/j.1525-1438.2007.00794.x] [PMID: 17362317]
[10]
Ezendam NP, Pijlman B, Bhugwandass C, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol 2014; 135(3): 510-7.
[http://dx.doi.org/10.1016/j.ygyno.2014.09.016] [PMID: 25281491]
[11]
Samimi MA, Zargarzadeh AH, Khadiby N, et al. Paclitaxel-induced peripheral neuropathy using NCI-CTC in Isfahan. Iran. J Pharm Res 2008; 4: 189-92.
[12]
Matsuo M, Ito H, Takemura Y, et al. Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study. J Anesth 2017; 31(4): 631-5.
[http://dx.doi.org/10.1007/s00540-017-2362-y] [PMID: 28451807]
[13]
Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials. J Clin Oncol 2016; 34(25): 3014-22.
[http://dx.doi.org/10.1200/JCO.2015.66.2346] [PMID: 27325863]
[14]
Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98(4): 779-88.
[http://dx.doi.org/10.1002/cncr.11548] [PMID: 12910523]
[15]
Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhauer E. Phase II trial of docetaxel in patients with recurrent malignant glioma: A study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 1996; 14(2): 203-6.
[http://dx.doi.org/10.1007/BF00210791] [PMID: 8913841]
[16]
van Gerven JM, Moll JW, van den Bent MJ, et al. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994; 30A(8): 1074-7.
[http://dx.doi.org/10.1016/0959-8049(94)90459-6] [PMID: 7654432]
[17]
Dehkordi FS, Momtaz H, Doosti A. Application of real-time PCR for detection of Aspergillus species in aborted ruminant foetuses. Bulg J Vet Med 2012; 15(1): 30-6.
[18]
Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, Goodman KA, Esfahani A. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer 2018; 18(1): 958.
[http://dx.doi.org/10.1186/s12885-018-4869-5] [PMID: 30290775]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy